Laminar Airflow in Severe Asthma for Exacerbation Reduction

NCT ID: NCT03058497

Last Updated: 2017-02-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 240 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-05-31
• Study Completion Date: 2017-01-31

Brief Summary

To ascertain whether home-based nocturnal TLA usage over a 12 month period can reduce exacerbations and improve asthma control and quality of life as compared to placebo, whilst being cost-effective and acceptable to adults with poorly-controlled, severe allergic asthma.

Detailed Description

We will include 222 adults, half of whom will be given a TLA device that is working, and the other half will be given a device which has been inactivated (the filtering process will be switched off, although the participants will not be able to tell that this has occurred). Which participant receives the working or deactivated device will be decided by a random process and will be unknown to the researcher and the participant. An engineering team from the manufacturer will install the device in the participants' home at the beginning of the study and be available throughout the study period to deal with any queries.

All participants will continue receiving their usual treatments. Participants will be in the study for 12 months, and will report their asthma attacks to the trial team whenever they occur during this period. In addition, they will visit the trial team 4 times (after 3, 6, 9 and 12 months) to assess their asthma control and quality of life. At the end of the trial, we will invite participants at each site to join a group discussion where researchers will explore the participant's thoughts about the TLA device. At the end of their participation in the trial, all participants who have used the device for more than 6 months, regardless of their initial study group, will be offered the opportunity to keep an active device in their home free of charge for a further four years.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Temperature-Controlled Laminar Airflow Device Active

Temperature-Controlled Laminar Airflow Device

Group Type: ACTIVE_COMPARATOR

Temperature-Controlled Laminar Airflow Device (Airsonett®)

Intervention Type: DEVICE

Temperature-Controlled Laminar Airflow Device Placebo

Temperature-Controlled Laminar Airflow Device

Group Type: PLACEBO_COMPARATOR

Temperature-Controlled Laminar Airflow Device (Airsonett®)

Intervention Type: DEVICE

Interventions

Temperature-Controlled Laminar Airflow Device (Airsonett®)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• A clinical diagnosis of asthma for ≥6 months with either: Airflow variability Airway reversibility Airway hyper-responsiveness

• Requirement for high-dose inhaled corticosteroids (ICS) (≥1000μg/day beclomethasone (BDP) or equivalent
• Poorly controlled asthma demonstrated by BOTH

≥2 severe asthma exacerbations, ACQ (7-point) score >1 at Screening Visit 1 and Randomisation Visit 2

• Atopic status
• Exacerbation free
• Able to use the TLA device during sleep on at least five nights per week
• Able to understand and give written informed consent prior

Exclusion Criteria

• Current smokers or ex-smokers abstinent for <6months
• Ex-smokers with ≥15 pack year smoking history
• Partner who is a current smoker and smokes within the bedroom where the TLA device is installed
• TLA device cannot be safely installed within the bedroom
• Intending to move out of study area within the follow-up period
• Documented poor treatment adherence
• Occupational asthma with continued exposure to known sensitising agents in the workplace
• Previous bronchial thermoplasty within 12 months of randomisation
• Treatment with Omalizumab (anti-IgE) within 120 days of randomisation
• Using long-term oxygen, Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV)
• Presence of clinically significant lung disease other than asthma, including smoking-related chronic obstructive pulmonary disease (COPD), bronchiectasis associated with recurrent bacterial infection, allergic bronchopulmonary aspergillosis (mycosis), pulmonary fibrosis, sleep apnoea, pulmonary hypertension, or lung cancer,
• Patients currently taking part in other interventional respiratory clinical trials

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Oxford

OTHER

Sponsor Role: collaborator

Portsmouth Hospitals NHS Trust

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anoop[ Chauhan

Role: STUDY_CHAIR

Portsmouth Hospitals NHS Trust

Locations

Portsmouth Hospital NHS Trust

Portsmouth, UK, United Kingdom

Countries

United Kingdom

Related Links

http://www.asthma-treatment.org.uk/

Trial Website

Other Identifiers

12/33/28

Identifier Type: -

Identifier Source: org_study_id